Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 7:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 4,796 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Total Occlusion of Artery of the Extremities
Interventions
FastWire System - Peripheral
Device
Lead sponsor
Versono Medical Ltd
Industry
Eligibility
18 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Wilmington, Delaware • Cocoa, Florida • Davenport, Iowa + 3 more
Conditions
Assess the Benefits From the AAISafeR/SafeR Algorithm of Symphony 2550 or REPLYTM DR in a Wide Range of Pacemaker Patients.
Interventions
Symphony DR 2550 and REPLY DR cardiac pacemakers
Device
Lead sponsor
LivaNova
Industry
Eligibility
Not listed
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Brighton, Massachusetts
Conditions
Parkinson's Disease, Movement Disorder Syndrome
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Classic Galactosemia
Interventions
AT-007, Placebo
Drug · Other
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Atlanta, Georgia • Ann Arbor, Michigan
Conditions
Osteoarthritis, Arthritis, Rheumatoid, Avascular Necrosis of Bone, Post-traumatic Arthritis, Rheumatoid Arthritis
Interventions
Total knee replacement
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
18 Years to 75 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
4
States / cities
La Jolla, California • Crystal River, Florida • Melbourne, Florida + 1 more
Recruiting Not applicable Interventional

Evaluation of the CONVIVO System

NCT05139277
Conditions
Glioblastoma, Glial Tumor, Brain Metastases, Meningioma, Schwannoma, Pituitary Tumor
Interventions
CONVIVO system, Conventional histologic evaluation
Diagnostic Test · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Digital Bonding vs. Direct Bonding Study

NCT06266130
Conditions
Orthodontic Brackets
Interventions
Treatment Group Digital Bonding Tray, Control Group Direct Bonding
Device
Lead sponsor
Solventum Orthodontics Corporation
Industry
Eligibility
11 Years and older
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Glendale, California • Kennebunk, Maine • Great Neck, New York + 2 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alinity s Anti-HCV II - Clinical Evaluation Protocol

NCT04862065
Conditions
Healthy
Interventions
Alinity s Anti-HCV II
Device
Lead sponsor
Abbott Transfusion Medicine
Industry
Eligibility
18 Years and older
Enrollment
16,388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
4
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee • San Antonio, Texas + 1 more
Conditions
B-Cell Lymphoproliferative Disorder
Interventions
IdentiClone Dx IGH (IC IGH Dx) Assay
Diagnostic Test
Lead sponsor
Invivoscribe, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
San Diego, California
Conditions
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-cell Chronic Lymphocytic Leukemia, B-cell Non Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Interventions
PBCAR20A, Fludarabine, Cyclophosphamide
Genetic · Drug
Lead sponsor
Precision BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Duarte, California • Stanford, California • New York, New York + 2 more
Conditions
Prostate Cancer Metastatic
Interventions
ARV-110
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
54
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 51 more
Conditions
Cognitive Function, Fatigue, Energy Levels, Mental Clarity, Brain Fog, Food Cravings
Interventions
Cellular Hydration Supplement
Dietary Supplement
Lead sponsor
Artah Nutrition Limited
Industry
Eligibility
25 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

NCT02852239
Conditions
Renal Impairment
Interventions
dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
DeBary, Florida • Berlin, New Jersey • Raleigh, North Carolina
Conditions
Non-Small Cell Lung Cancer
Interventions
bevacizumab, erlotinib HCl, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
4
States / cities
Vallejo, California • Athens, Georgia • Kansas City, Kansas + 1 more
Conditions
Stroke, Venous Thrombosis, Atrial Fibrillation, Atrial Flutter
Interventions
Genotype-guided dosing algorithm for warfarin, Clinical-guided dosing algorithm for warfarin
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 15 more
Conditions
Pain
Interventions
Not listed
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Atlanta, Georgia • Louisville, Kentucky • New York, New York
Not listed Not applicable Interventional Accepts healthy volunteers

Fat Reduction in the Flanks Area vs. Control

NCT02465775
Conditions
Flanks Fat Reduction vs. Control
Interventions
UltraShape treatment
Device
Lead sponsor
Syneron Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Metairie, Louisiana • Hunt Valley, Maryland • Nashville, Tennessee
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, First Degree Relative, Pathologic Stage 0 Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Interventions
Informational Intervention, Survey Administration
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
1,160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
New Brunswick, New Jersey • Houston, Texas
Conditions
Venous Leg Ulcer, Diabetic Foot Ulcer
Interventions
EscharEx (EX-02 formulation)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Tamarac, Florida • Las Vegas, Nevada • Chapel Hill, North Carolina
Conditions
Tuberculosis, HIV Infections
Interventions
Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6)
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 17 more
Conditions
Neoplasms
Interventions
Qualitative Interviews, PROMIS Physical Function Items
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mountlake Terrace, Washington
Conditions
Lipedema, Dercum Disease
Interventions
RZL-012
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
20 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Completed Not applicable Interventional Accepts healthy volunteers

BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test

NCT04959760
Conditions
COVID-19 Respiratory Infection
Interventions
The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.
Diagnostic Test
Lead sponsor
Abbott Rapid Diagnostics Jena GmbH
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Chicago, Illinois • Durham, North Carolina • Powdersville, South Carolina + 2 more
Conditions
Peyronie's Disease
Interventions
H-100, Placebo
Drug
Lead sponsor
Hybrid Medical
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Robbinsdale, Minnesota